Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Creon

Allergan logo

Allergan inks $2.1bn deal to buy cosmetic drug firm Kythera

Company will add Kythera’s double chin therapy Kybella to its portfolio

Allergan logo

More waiting for Allergan and Gedeon Richter’s antipsychotic

FDA announced it will take another three months to review cariprazine for schizophrenia

EU flag

Three cancer immunotherapies amongst new CHMP approvals

BMS’ Evotaz also amongst eight new medicine recommendations

- PMLiVE

Kythera bags FDA approval for double chin therapy

Comes as cosmetics industry sees major growth

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo backed as melanoma therapy in EU

First checkpoint inhibitor to be recommended for approval in the region

EISAI

Eisai’s thyroid cancer drug Lenvima nears EU approval

Positive recommendation by the CHMP could see the orphan drug used in Europe within three months

- PMLiVE

Actavis completes $70.5bn Allergan acquisition

Finalisation comes after bidding war with deal-hungry Valeant

EU flag

New cancer meds and drug extensions top CHMP recommendations

Drugs for rare disease, oncology and diabetes top regulator’s endorsements

EU flag

Jinarc backed for European approval in rare kidney disease

Positive opinion for Otsuka comes just before rare disease awareness day

- PMLiVE

NICE recommends Ozurdex for diabetic eye condition

Draft guidance cites implant as option for patients with diabetic macular oedema

- PMLiVE

Abraxane on course for lung cancer indication in EU

CHMP backs news indication for Celgene drug

EU flag

Antibiotics among 7 new drugs backed by EMA

The Medicines Company’s Orbactiv and Cubist’s Sivextro set for European approval

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links